Interleukin (IL)-24 is an excellent therapeutic gene for cancer therapy. In this work, IL-24 was inserted into Ad.sp-E1A(Δ24), an oncolytic adenovirus with a 24-bp deletion in the E1A gene, which was driven by the survivin promoter to form Ad.sp-E1A(Δ24)-IL-24. Ad.sp-E1A(Δ24)-IL-24 has an excellent antitumor effect in vitro for human nasopharyngeal, liver, lung, and cervical carcinoma cell lines but does no or little damage to normal cell lines L-02 and WI38. Furthermore, it achieved nearly complete inhibition (although not elimination) of NCI-H460 lung carcinoma growth in nude mice. The antitumor efficacy of Ad.sp-E1A(Δ24)-IL-24 on NCI-H460 cells was clearly mediated by apoptosis, because it induced caspase-3 and poly(ADP-ribose) polymerase cleavage. This is the first report of Ad.sp-E1A(Δ24)-IL-24 with such an excellent, broad, and specific antitumor effect in vitro and nearly complete inhibition of lung tumor growth in vivo.
Get full access to this article
View all access options for this article.
References
1.
AdachiY., ReynoldsP.N., YamamotoM., WangM., TakayamaK., MatsubaraS., MuramatsuT., CurielD.T.2001. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res., 61:7882–7888.
2.
AdidaC., BerrebiD., PeuchmaurM., Reyes-MugicaM., AltieriD.C.1998. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351:882–883.
3.
AltieriD.C.2008. New wirings in the survivin networks. Oncogene, 27:6276–6284.
4.
AmbrosiniG., AdidaC., AltieriD.C.1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3:917–921.
5.
BeltramiE., PlesciaJ., WilkinsonJ.C., DuckettC.S., AltieriD.C.2004. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem., 279:2077–2084.
6.
BendrikC., RobertsonJ., GauldieJ., DabrosinC.2008. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res., 68:3405–3412.
7.
Blanc-BrudeO.P., MesriM., WallN.R., PlesciaJ., DohiT., AltieriD.C.2003. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res., 9:2683–2692.
8.
CaudellE.G., MummJ.B., PoindexterN., EkmekciogluS., MhashilkarA.M., YangX.H., RetterM.W., HillP., ChadaS., GrimmE.A.2002. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J. Immunol., 168:6041–6046.
9.
ChadaS., SuttonR.B., EkmekciogluS., EllerhorstJ., MummJ.B., LeitnerW.W., YangH.Y., SahinA.A., HuntK.K., FusonK.L., PoindexterN., RothJ.A., RameshR., GrimmE.A., MhashilkarA.M.2004. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int. Immunopharmacol., 4:649–667.
10.
ComminsS., SteinkeJ.W., BorishL.2008. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol., 121:1108–1111.
11.
CunninghamC.C., ChadaS., MerrittJ.A., TongA., SenzerN., ZhangY., MhashilkarA., ParkerK., VukeljaS., RichardsD., HoodJ., CoffeeK., NemunaitisJ.2005. Clinical and local biological effects of an intratumoral injection of mda-7 (IL-24; INGN 241) in patients with advanced carcinoma: A phase I study. Mol. Ther., 11:149–159.
12.
EagerR., HarleL., NemunaitisJ.2008. Ad-MDA-7; INGN 241: A review of preclinical and clinical experience. Expert Opin. Biol. Ther., 8:1633–1643.
HallenbeckP.L., ChangY.N., HayC., GolightlyD., StewartD., LinJ., PhippsS., ChiangY.L.1999. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10:1721–1733.
20.
InoueS., ShankerM., MiyaharaR., GopalanB., PatelS., OidaY., BranchC.D., MunshiA., MeynR.E., AndreeffM., TanakaF., MhashilkarA.M., ChadaS., RameshR.2006. MDA-7/IL-24-based cancer gene therapy: Translation from the laboratory to the clinic. Curr. Gene Ther., 6:73–91.
21.
KamizonoJ., NaganoS., MurofushiY., KomiyaS., FujiwaraH., MatsuishiT., KosaiK.2005. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res., 65:5284–5291.
22.
Karczmarek-BorowskaB., FilipA., WojcierowskiJ., SmolenA., PileckaI., JablonkaA.2005. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: In situ hybridization study. Folia Histochem. Cytobiol., 43:237–242.
23.
LebedevaI.V., SuZ.Z., ChangY., KitadaS., ReedJ.C., FisherP.B.2002. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene, 21:708–718.
24.
LeeJ.H., ZabnerJ., WelshM.J.1999. Delivery of an adenovirus vector in a calcium phosphate coprecipitate enhances the therapeutic index of gene transfer to airway epithelia. Hum. Gene Ther., 10:603–613.
25.
LiB., LiuX., FanJ., QiR., BoL., GuJ., QianQ., QianC., LiuX.2006. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J. Gene Med., 8:1232–1242.
26.
LiF., AltieriD.C.1999a. The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res., 59:3143–3151.
27.
LiF., AltieriD.C.1999b. Transcriptional analysis of human survivin gene expression. Biochem. J., 344:305–311.
28.
LiF., AmbrosiniG., ChuE.Y., PlesciaJ., TogninS., MarchisioP.C., AltieriD.C.1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396:580–584.
29.
LiuX.Y.2001. A new anticancer strategy: Gene-virotherapy therapy of cancer. Chin. J. Cancer Biother., 8:1.
30.
LiuX.Y.2006. Targeting gene-virotherapy of cancer and its prosperity. Cell Res., 16:879–886.
31.
LuB., MuY., CaoC., ZengF., SchneiderS., TanJ., PriceJ., ChenJ., FreemanM., HallahanD.E.2004. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res., 64:2840–2845.
32.
MitaA.C., MitaM.M., NawrockiS.T., GilesF.J.2008. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res., 14:5000–5005.
33.
MiyaharaR., BanerjeeS., KawanoK., EffersonC., TsudaN., MiyaharaY., IoannidesC.G., ChadaS., RameshR.2006. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther., 13:753–761.
34.
NassarA., LawsonD., CotsonisG., CohenC.2008. Survivin and caspase-3 expression in breast cancer: Correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl. Immunohistochem. Mol. Morphol., 16:113–120.
35.
NettelbeckD.M., RiveraA.A., BalagueC., AlemanyR., CurielD.T.2002. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res., 62:4663–4670.
36.
O'SheaC.C., JohnsonL., BagusB., ChoiS., NicholasC., ShenA., BoyleL., PandeyK., SoriaC., KunichJ., ShenY., HabetsG., GinzingerD., McCormickF.2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell, 6:611–623.
37.
PengZ.2005. Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther., 16:1016–1027.
38.
PetersenJ., HaganI.M.2003. S. pombe aurora kinase/survivin is required for chromosome condensation and the spindle checkpoint attachment response. Curr. Biol., 13:590–597.
39.
RajD., LiuT., SamadashwilyG., LiF., GrossmanD.2008. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis, 29:194–201.
40.
RameshR., MhashilkarA.M., TanakaF., SaitoY., BranchC.D., SiegerK., MummJ.B., StewartA.L., BoquoiA., DumoutierL., GrimmE.A., RenauldJ.C., KotenkoS., ChadaS.2003. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res., 63:5105–5113.
41.
RodriguezR., SchuurE.R., LimH.Y., HendersonG.A., SimonsJ.W., HendersonD.R.1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57:2559–2563.
42.
SaekiT., MhashilkarA., SwansonX., Zou-YangX.H., SiegerK., KawabeS., BranchC.D., ZumsteinL., MeynR.E., RothJ.A., ChadaS., RameshR.2002. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene, 21:4558–4566.
43.
SauaneM., GuptaP., LebedevaI.V., SuZ.Z., SarkarD., RandolphA., ValerieK., GopalkrishnanR.V., FisherP.B.2006. N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and “bystander” antitumor activity. Cancer Res., 66:11869–11877.
44.
SauaneM., SuZ.Z., GuptaP., LebedevaI.V., DentP., SarkarD., FisherP.B.2008. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc. Natl. Acad. Sci. U.S.A., 105:9763–9768.
45.
ShinouraN., HamadaH.2003. Gene therapy using an adenovirus vector for apoptosis-related genes is a highly effective therapeutic modality for killing glioma cells. Curr. Gene Ther., 3:147–153.
46.
SuZ., EmdadL., SauaneM., LebedevaI.V., SarkarD., GuptaP., JamesC.D., RandolphA., ValerieK., WalterM.R., DentP., FisherP.B.2005. Unique aspects of mda-7/IL-24 antitumor bystander activity: Establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene, 24:7552–7566.
47.
TongA.W., NemunaitisJ., SuD., ZhangY., CunninghamC., SenzerN., NettoG., RichD., MhashilkarA., ParkerK., CoffeeK., RameshR., EkmekciogluS., GrimmE.A., Van Wart HoodJ., MerrittJ., ChadaS.2005. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL-24): Biologic outcome in advanced cancer patients. Mol. Ther., 11:160–172.
48.
VirreyJ.J., GuanS., LiW., SchonthalA.H., ChenT.C., HofmanF.M.2008. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am. J. Pathol., 173:575–585.
49.
WangJ.2008. Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy, 4:947–948.
50.
WangX., YeZ., ZhongJ., XiangJ., YangJ.2007. Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis. Cancer Biother. Radiopharm., 22:56–63.
51.
Warnecke-EberzU., BaldusS.E., BollschweilerE., HoelscherA.H., MetzgerR.2008. Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis. Anticancer Res., 28:1525–1529.
52.
WuB., HuangC., Kato-MaedaM., HopewellP.C., DaleyC.L., KrenskyA.M., ClaybergerC.2007. IL-24 modulates IFN-γ expression in patients with tuberculosis. Immunol. Lett., 117:57–62.
53.
XieX., XiaW., LiZ., KuoH.P., LiuY., DingQ., ZhangS., SpohnB., YangY., WeiY., LangJ.Y., EvansD.B., ChiaoP.J., AbbruzzeseJ.L., HungM.C.2007. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 12:52–65.
54.
XieY., ShengW., XiangJ., YeZ., ZhuY., ChenX., YangJ.2008. Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis. Cancer Biother. Radiopharm., 23:310–320.
55.
YangX., XiongG., ChenX., XuX., WangK., FuY., YangK., BaiY.2008. Survivin expression in esophageal cancer: Correlation with p53 mutations and promoter polymorphism. Dis. Esophagus, 22:223–230.
ZhaoL., DongA., GuJ., LiuZ., ZhangY., ZhangW., WangY., HeL., QianC., QianQ., LiuX.2006. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther., 13:1011–1022.
